Over the river and through the woods, avoiding bankruptcy court we go. AVITA Medical announced an improving quarterly performance and promised to achieve cash breakeven operations in Q4 2026. Throw in a low daily trading volume, high short interest, and a "left for dead" attitude among investors, and you get a one-day stock surge of 63%.

The outlook is certainly improving, but AVITA Medical isn't out of the woods yet.

If it liquidated itself right now, selling all assets and paying all liabilities, then it would still owe $27 million. (For context, even the heavily-flawed Coherus Oncology would be worth $61 million after the same exercise.) That's primarily because AVITA Medical has a $46 million debt overhang and just $11 million of cash+. Although management broke towards transparency by breaking out individual product revenue for the first time, a careful reading of SEC filings shows PermeaDerm isn't ramping and international expansion remain a slog. Operations are leaning toward greener shoots nonetheless.

In addition to keeping the plane in the air, management's primary decision will be how – or if – to add more breathing room and financial firepower. Achieving cash breakeven operations doesn't mean the business will immediately become a cash cow. If it can only generate $15 million or so in full-year 2027 cash flow, then that imposes certain speed limits with respect to making intelligent growth investments or providing a cushion against setbacks, especially since the milestone will be achieved at austerity-level operating expenses.

A relatively low valuation and low outstanding share count mean it'll be difficult to raise a meaningful amount of cash with a public offering of common stock. Responsible public offerings typically issue 10% to 15% dilution, which would translate to roughly $15 million to $20 million at the post-surge valuation. Perhaps the strategic tie-up with Perceptive Advisors (which assumed the role of creditor from OrbiMed) will help the wound care specialist land a private placement from a committed investor.

That's the objective take. If you dare to pick up the pompoms for a brief moment, then an AVITA Medical that turns itself right 'round baby right 'round could be firmly back in value territory.

Management is nearing the finish line for negotiating a new national Medicare code for ReCell in 2027, which would replace the region-by-region codes that have played a significant role in stalling revenue growth in recent years. These payment codes and rates are typically announced in late October or November of each calendar year and go into effect in early January of the next (that's how it works when we have a functioning federal government anyway…).

In other words, if AVITA Medical can grow revenue at least 20% per year and isn't burning cash, then a fair valuation based on full-year 2027 revenue would be at least $476 million. Sprinkle in a capital raise that results in 17.5% dilution, and you still get a fair value equivalent to $11.97 per share. This might be a little conservative considering the business expects to grow sales at least 20% in 2026, but there are several important things to prove before getting too carried away.

By the Numbers

AVITA Medical notched its first-ever $20 million revenue quarter in Q2 2026. That was propelled by ReCell waking from its long slumber, as the brand delivered year-over-year growth for the first time in a year.

The flagship brand was responsible for 88% of total commercial revenue, or $19.0 million of $21.6 million. ReCell grew 13% compared to the prior-year period after wading through declines in each of the previous three quarters. Cohealyx and PermeaDerm drove the other $2.4 million in product revenue, while lease revenue from ReCell GO devices contributed the balance.

Diversifying the revenue mix will come at the expense of gross margin, but there's plenty of wiggle room relative to the three-year average of 84.5% delivered from 2022 through 2024. AVITA Medical achieved a gross margin of "only" 81.9% in the second quarter. Importantly, that led to $17.8 million in gross profit, which nearly offset the $18.0 million in cash expenses from sales, marketing, general, and administrative activities.

‍

AVITA Medical reported an operating loss of $6.9 million, including non-cash expenses. An operating margin of negative 32% was the smallest since the company launched ReCell in late 2019. Operating cash burn of $3.5 million was the lowest since Q4 2022, which puts the company on track to meet management's guidance to achieve cash flow breakeven operations in the final frame of 2026.

‍

Investors should be cognizant of an upcoming accounting quirk. The deterioration of the business in the second half of 2025 means year-over-year revenue growth in Q3 2026 and Q4 2026 will appear absolutely amazing.

Whereas the current quarter compared $21.7 million in revenue to the year-ago total of $18.4 million, the upcoming Q3 2026 period will compare more than $22 million in revenue to the year-ago total of just $15.6 million. That'll be reported as more than 40% growth (!). Of course, it's really a reminder of just how far the business slid last year. Although not impossible, I wouldn't yet expect the business to grow revenue by 40% in 2027.

‍

Product mix

ReCell will continue to be the primary contributor for the business for the foreseeable future, but a more diverse wound-care portfolio is beginning to take shape.

The company's three products can sometimes be used to treat the same skin wound, especially severe burns. Cohealyx is a dermal matrix used in the deepest part of a wound (dermis), which adds structure to accelerate wound healing and blood vessel regrowth. ReCell is used on top of that (epidermis) to exponentially increase wound-edge surface area, which accelerates skin regrowth, reduces scarring, and improves pigmentation. PermeaDerm is a dressing applied on top of the wound bed to protect the healing environment and optimize moisture.

Cohealyx is now responsible for 8% of total commercial revenue, up from 2% in the year-ago period. PermeaDerm added another 3% to the commercial haul, although the product is not ramping consistently and appears stuck near $0.6 million in quarterly revenue.

‍

In economic terms, Cohealyx is more important than PermeaDerm. The dermal matrix product can generate over $20,000 in revenue per application, which is 10x that for the wound dressing. Although Cohealyx isn't needed for every type of burn or wound, it's a more differentiated product with clinical value that's difficult to replicate. By contrast, doctors and trauma teams might be more willing to use the wound dressings they've always used, as they're basically all the same. That suggests AVITA Medical might be better off throwing in PermeaDerm as a sweetener to close deals. That's still valuable, just in a different sense.

Revenue guidance

Management appears confident enough in the trajectory of the business to raise full-year 2026 revenue guidance. The prior range ($80 million to $85 million) had a midpoint of $82.5 million. Updated guidance ($86 million to $89 million) expects a midpoint of $87.5 million.

AVITA Medical generated $40.9 million in 1H 2026 revenue. That means the business needs to deliver roughly $46.6 million in 2H 2026 revenue to meet the midpoint of guidance. If achieved, it would be a welcome return to growth.

‍

Snakebitten investors wouldn't be blamed for adopting a "show me, don't tell me" stance to the company's growth projections. However, it is noteworthy that the low-end of revenue guidance is $86 million. To unlock the remaining $10 million in its credit facility, AVITA Medical must achieve $85 million in trailing twelve-month (TTM) revenue by the end of March 2027. It might notch that milestone one quarter ahead of the deadline.

In other words, even slightly missing revenue guidance would likely be interpreted as a net positive for the business and the stock – so long as the company generates at least $85 million in full-year 2026 revenue.

News Flow & Modeling Insights

The current model has been updated to reflect a return to growth in 2027. It hinges on continued execution and the finalization of a proposed payment code update from the Centers for Medicare & Medicaid Services (CMS).

CMS has proposed harmonizing the payment code for ReCell at the national level, which would replace the current region-by-region payment codes. That should simplify billing and potentially accelerate reimbursement. For example, private insurance rates are generally based on the Medicare rate, but there are currently multiple rates depending on geography. That doesn't make much sense, creates unnecessary friction for large trauma centers that operate in multiple states, and could have played a role in slowing adoption.

CMS has also proposed higher reimbursement rates for outpatient treatment settings, although this is a relatively insignificant market for AVITA Medical at the moment.

The current model is based on full-year 2027 operating metrics, including the following:

• Revenue of $108.570 million, representing roughly 25% growth from the prior year
• Gross margin of 79.7%
• Operating cash flow of $14.3 million
• A public offering of common stock and/or private placement totaling dilution of 17.5%

Margin of Safety & Conviction

(Increased.)

AVITA Medical is considered a Future Compounder position with the following Conviction rating.

• 1 = High
• 2 = Above Average
• 3 = Average (upgraded one level)
• 4 = Below Average

The estimated fair valuation based on my current model is below:

• Market close August 13: $8.01 per share
• Modeled Fair Valuation: $11.97 per share

AVITA Medical reported 30.927 million shares outstanding as of August 3, 2026. The modeled fair valuation above assumes 42.363 million shares outstanding, which is equivalent to 17.5% dilution.

Further Reading

• August 2026 press release announcing Q2 2026 operating results
• August 2026 regulatory filing (10-Q) detailing Q2 2026 operating results
• Quarterly business update Discord thread